Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Initiates Buyback of $10M of Shares

NEW YORK (GenomeWeb News) – Qiagen said in a regulatory document today that it began buying back the euro equivalent of $10 million of its shares on Sept. 10 in the first tranche of a share repurchasing program.

The company will buy back a maximum of 750,000 shares of its common stock on the electronic trading platform of the Frankfurt Stock Exchange during the tranche, which will last until Nov. 1, Qiagen said in a document filed with the US Securities and Exchange Commission. The maximum purchase price on a per share basis will not exceed by more than 10 percent the average closing price for the last five trading days prior to the day of purchase on the exchange.

The company said during its second quarter earnings announcement that it was repurchasing up to $100 million of its shares in a new buyback program.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.